LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LCB-71’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LCB-71 (ABL-202) is under development for the treatment of hematological tumors including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, acute lymphoblastic leukemia, Hodgkin and non-Hodgkin B-cell lymphoma, Diffuse Large B Cell Lymphoma and solid tumors including triple-negative breast cancer, non-small cell lung cancer, and gastric cancer. The drug candidate is an antibody-drug conjugate (ADC) comprises of pyrrolobenzodiazepine (PBD) protoxin payload (Payload) and linker. It acts by targeting ROR1. The drug candidate is administered through intravenous route.
CStone Pharmaceuticals overview
CStone Pharmaceuticals is a biopharmaceutical company. It develops and commercializes immuno-oncology and precision medicine to address the unmet medical needs of cancer patients. The company’s pipeline product portfolio includes Ivosidenib (CS3010) for the treatment of acute myeloid leukemia (AML); CS1001 to treat solid tumors; Avapritinib (CS3007) for the treatment of liver diseases; CS1002, CS1003, CS3006, CS3003, CS3002 to treat solid tumors. CStone Pharmaceuticals operates clinical research institutions for developing anti-cancer drugs. The company’s partners include Agios Inc, Blueprint Medicines Corp and WuXi Biologics. CStone Pharmaceuticals is headquartered in Shanghai, China.
For a complete picture of LCB-71’s drug-specific PTSR and LoA scores, buy the report here.